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Abstract:	
Growth	hormone	deficiency	(GHD)	can	present	at	any	time	of	life	from	the	neonatal	period	to	adulthood,	as	
a	 result	of	congenital	or	acquired	 insults.	 It	can	present	as	an	 isolated	problem	(IGHD)	or	 in	combination	
with	 other	 pituitary	 hormone	 deficiencies	 (CPHD).	 Pituitary	 deficits	 can	 evolve	 at	 any	 time	 from	 GHD	
diagnosis.	 The	 number,	 severity	 and	 timing	 of	 occurrence	 of	 additional	 endocrinopathies	 are	 highly	
variable.			
The	 risk	 of	 progression	 from	 IGHD	 to	 CPHD	 in	 children	 varies	 depending	 on	 the	 etiology	 (idiopathic	 vs	
organic).	 The	 highest	 risk	 is	 displayed	 by	 children	with	 abnormalities	 in	 the	Hypothalamo-Pituitary	 (H-P)	
region.	 Heterogeneous	 data	 have	 been	 reported	 on	 the	 type	 and	 timing	 of	 onset	 of	 additional	 pituitary	
hormone	 deficits,	 with	 TSH	 deficiency	 being	 most	 frequent	 and	 Diabetes	 insipidus	 the	 least	 frequent	
additional	deficit	 in	the	majority,	but	not	all,	of	the	studies.	ACTH	Deficiency	may	gradually	evolve	at	any	
time	 during	 follow-up	 in	 children	 or	 adults	 with	 childhood	 onset	 IGHD,	 particularly	 (but	 not	 only)	 in	
presence	of	H-P	abnormalities	and/or	TSH	Deficiency.	Hence	there	 is	a	need	 in	these	patients	for	 lifelong	
monitoring	 for	 ACTH	 deficiency.	 GH	 treatment	 unmasks	 central	 hypothyroidism	mainly	 in	 patients	 with	
organic	GHD,	but	all	patients	 starting	GH	should	have	 their	 thyroid	 function	monitored	closely.	Main	 risk	
factors	 for	development	of	CPHD	 include	organic	 etiology,	H-P	abnormalities	 (in	particular	pituitary	 stalk	
abnormalities,	 empty	 sella	 and	 ectopic	 posterior	 pituitary),	 midline	 brain	 (corpus	 callosum)	 and	 optic	
nerves	abnormalities,	genetic	defects	and	longer	duration	of	follow-up.	
The	 current	 available	 evidence	 supports	 longstanding	 recommendations	 for	 the	 need,	 in	 all	 patients	
diagnosed	with	IGHD,	of	a	careful	and	indefinite	follow-up	for	additional	pituitary	hormone	deficiencies.	
	
Highlights:	
• This	 review	 commences	 with	 a	 general	 overview	 on	 isolated	 GH	 deficiency	 and	 the	 current	
recommendation	on	monitoring	for	the	risk	of	development	of	additional	hormonal	deficiencies.	
• The	evidence	pertaining	to	the	risk	of	progression	from	IGHD	to	CPHD	and	on	the	type	and	timing	
of	additional	pituitary	hormone	deficiencies	is	then	summarized.	
• The	 risk	 of	 developing	 central	 hypoadrenalism	 in	 adults	 with	 childhood-onset	 GHD	 and	 central	
hypothyroidism	after	the	start	of	GH	therapy	is	also	discussed.		
• Finally,	the	main	risk	factors	associated	with	development	of	CPHD	are	evaluated.		
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Introduction	
	
Growth	hormone	deficiency	(GHD)	can	present	at	any	time	of	life	from	the	neonatal	period	to	adulthood,	
and	can	be	a	result	of	congenital	or	acquired	insults.		
In	congenital	cases,	GHD	can	be	found	in	association	with	brain	and	midline	facial	abnormalities	or	can	be	
due	 to	 mutations	 in	 genes	 involved	 in	 hypothalamo-pituitary	 (H-P)	 development	 or	 in	 the	 GHRH/GH	
pathway.	Acquired	causes	include	trauma,	central	nervous	system	(CNS)	infections,	H-P	tumours,	infiltrative	
or	granulomatous	diseases,	cranial	 irradiation,	surgery	or	infarction	of	the	H-P	region.	Patients	in	whom	a	
clear	 etiology	 cannot	 be	 identified	 are	 considered	 “idiopathic”.	 The	 latter	 category	 accounts	 for	 most	
individuals	with	childhood-onset	GHD,	whereas	it	is	exceptionally	rare	in	adults	[1].					
Short	stature	with	a	poor	growth	velocity	may	be	the	only	clinical	presenting	feature	of	GHD	in	childhood.	
Other	 key	 features	 in	 the	 history	 and	 physical	 examination	 include:	 1)	 in	 the	 neonate:	 hypoglycaemia,	
prolonged	 jaundice,	microphallus	with	 undescended	 testes,	 or	 traumatic	 delivery;	 2)	 a	 history	 of	 cranial	
irradiation;	 3)	 a	 history	 of	 head	 trauma	 or	 CNS	 infection;	 4)	 consanguinity	 and/or	 an	 affected	 family	
member;	and	5)	craniofacial	midline	abnormalities	[2].	When	occurring	after	completion	of	linear	growth,	
GHD	can	be	more	difficult	to	identify.	Adult	patients	at	risk	of	GHD	and	therefore	needing	testing	include	1)	
those	with	signs	and	symptoms	of	H-P	disease,	2)	those	who	have	received	cranial	irradiation	or	treatment	
for	 tumours,	 3)	 those	 with	 traumatic	 brain	 injury	 or	 subarachnoid	 hemorrhage	 [3].	 Additionally,	 clinical	
features	of	Langerhans	cell	histiocytosis	and	sarcoidosis	may	be	present	and	indicate	a	need	for	testing	of	
the	HP	axis.	
It	is	well-known	that	GHD	can	present	as	an	isolated	problem	(IGHD)	or	in	combination	with	other	pituitary	
hormone	deficiencies	(CPHD).	 	Pituitary	deficits	can	evolve	at	any	time	from	GHD	diagnosis.	The	number,	
severity	and	timing	of	occurrence	of	additional	endocrinopathies	are	highly	variable.		
Current	paediatric	guidelines	state	that,	in	patients	with	an	initial	diagnosis	of	IGHD,	particularly	those	with	
an	ectopic	posterior	pituitary	or	other	developmental	abnormalities,	the	clinician	should	be	alert	to	the	risk	
of	 the	 development	 of	 CPHD	 [2].	 Similarly,	 adult	 guidelines	 suggest	 that	 thyroid	 and	 adrenal	 function	
should	be	monitored	during	GH	therapy	[1].	
However,	no	specific	recommendations	exist	on	the	process	of	measurement	(eg	baseline	vs	dynamic	tests)	
and	 on	 the	 frequency	 of	 anterior	 pituitary	 function	 monitoring	 in	 patients	 with	 IGHD.	 Most	 paediatric	
endocrinologists	 routinely	obtain	 thyroid	 function	 tests	on	all	 poorly	 growing	 children	 regardless	of	 their	
GH	 status.	 However,	 the	 decision	 whether	 to	 evaluate	 the	 other	 axes	 in	 all	 children	 with	 IGHD	 varies	
between	centres	and	clinicians.	
The	 aim	 of	 this	 review	 is	 to	 summarize	 the	 current	 evidence	 on	 the	 progression	 from	 IGHD	 to	 CPHD	 in	
childhood,	adolescence	and	adulthood.	The	review	will	particularly	focus	on	the	type	of	additional	pituitary	
deficiencies,	on	the	timing	of	occurrence	and	on	the	risk	factors	for	the	evolution	of	endocrinopathies.				
	
Risk	of	progression	from	IGHD	to	CPHD	and	type	and	timing	of	additional	pituitary	deficits	
	
The	results	from	the	main	studies	analyzing	the	risk	of	progression	from	IGHD	to	CPHD	are	summarized	in	
Table	1.	
In	a	large	prospective,	multinational	study	(GeNeSIS),	data	were	analyzed	in	5805	paediatric	patients	with	
idiopathic	IGHD.		CPHD	developed	in	2.0%	in	the	overall	cohort,	and	in	5.5%	among	children	followed	for	a	
minimum	of	3.5	years.	The	relative	frequency	of	additional	deficiencies	was	TSH	>	LH/FSH	>	ADH	>	ACTH.	
Median	 interval	 from	diagnosis	of	GHD	to	additional	pituitary	hormone	deficiency	was	1.9	years	 for	TSH,	
2.4	years	for	both	ADH	and	ACTH,	and	3.3	years	for	LH/FSH	[4].	 In	716	paediatric	patients	from	the	same	
database	 with	 IGHD	 due	 to	 organic	 causes,	 there	 was	 a	 higher	 frequency	 of	 CPHD	 (9.9%	 in	 the	 overall	
cohort,	and	20.7%	in	the	subgroup	followed	up	for	a	minimum	of	3.5	years).	The	most	frequent	additional	
deficiencies	were	TSH	and	LH/FSH	[5].	In	a	retrospective	study	of	83	patients	initially	diagnosed	as	IGHD	in	
childhood,	 45%	 developed	 CPHD	 after	 a	median	 follow-up	 of	 5.4	 years.	 The	 authors	 suggested	 that	 the	
higher	 prevalence	 of	 evolution	 from	 IGHD	 to	 CPHD,	 as	 compared	 to	 previous	 reports,	 was	 partially	
explained	by	 the	 longer	 duration	of	 follow-up	 and	by	 the	 single	 centre	 nature	 of	 the	 study	with	 routine	
clinical	and	laboratory	assessments	increasing	the	sensitivity	of	detection	of	new	hormone	deficiencies.	LH	
and	 FSH	 deficiencies	 (38%)	 were	 the	most	 common	 additional	pituitary	 deficits,	 followed	 by	 TSH	 (31%),	
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ACTH	(12%)	and	ADH	deficiency	(5%).	ADH	deficiency	(3.1	±	1	years	from	GHD	diagnosis)	presented	earlier	
and	ACTH	deficiency	(9.3	±	3.5	years)	presented	later	during	follow	up	compared	to	LH/FSH	(8.3	±	4	years)	
and	 TSH	 (7.5	 ±	 5.6	 years)	 deficiencies.	 Since	 half	 of	 the	 patients	 with	 IGHD	 developed	 the	
second	hormone	deficiency	5	years	after	the	IGHD	diagnosis,	the	authors	reinforced	the	need	for	life-long	
monitoring	of	pituitary	function	in	these	patients	[6].		
Several	authors	have	focused	on	the	progression	from	IGHD	to	CPHD	in	patients	with	H-P	abnormalities..	A	
recent	 large	international	database	confirmed	the	value	of	classification	of	GHD	patients	by	 the	presence	
and	 type	 of	 H-P	imaging	abnormalities.	 Thirty-five	 percent	 of	 patients	 with	 H-P	 structural	abnormalities	
developed	additional	hormonal	deficiencies	and,	when	compared	with	patients	with	idiopathic	GHD,	they	
had	more	severe	endocrine	phenotypes	[7].	Similarly,	in	a	study	of	103	patients,	72	of	whom	had	IGHD	and	
31	 had	 CPHD,	 structural	 H-P	 abnormalities	 were	 observed	 in	 48.6%	patients	 with	 IGHD	 and	 93.5%	with	
CPHD.	Over	 a	mean	 follow-up	 period	 of	 4.5	 years,	 5.4%	 of	 subjects	with	 an	 abnormal	MRI	 and	 none	 of	
those	with	 a	 normal	MRI	 progressed	 from	 IGHD	 to	 CPHD.	 Amongst	 CPHD	 patients,	 an	 ectopic	 posterior	
pituitary/absent	 pituitary	 stalk	 was	 present	 in	 80%	 of	 subjects	 with	 associated	 hypocortisolism	 ±	
hypothyroidism	as	compared	 to	18.2%	of	 subjects	with	hypogonadism	 [8].	 In	a	 retrospective	 longitudinal	
study	 of	 67	 patients	with	 pituitary	 stalk	 interruption	 syndrome	 (absent	 or	 thin	 pituitary	 stalk,	 absent	 or	
hypoplastic	 anterior	 pituitary	 lobe	 and/or	 ectopic	 posterior	 pituitary	 lobe)	 all	 patients	 had	 GHD	 at	
diagnosis.	CPHD	was	found	in	all	patients	presenting	in	the	neonatal	period	but	only	in	34%	of	the	patients	
presenting	 later	 in	 life.	 CPHD	 in	 the	 neonatal	 group	 was	 complete	 (i.e.,	 associated	 GH,	 ACTH,	 TSH	 and	
LH/FSH	deficiencies)	in	9	of	10	patients.	This	severe	phenotype	was	related	to	severely	abnormal	pituitary	
development	 (i.e.,	 anterior	 pituitary	 lobe	 not	 visible).	 In	 21	 patients	 presenting	with	 growth	 retardation	
followed	 until	 final	 height	 attainment,	 the	 authors	 were	 able	 to	 document	 a	 progressive	 worsening	 of	
endocrine	 function	 in	 44.6%	 of	 the	 cases	 (follow-up:	 7.3	 -	 16.6	 years).	 Re-evaluation	 at	 completion	 of	
growth	 of	 these	 21	 patients	 showed	 that	 17	 patients	 (81%)	 had	 CPHD;	 this	 frequency	 was	 no	 longer	
different	 from	 that	 of	 neonatal	 patients.	 In	 summary,	 in	 contrast	 to	 patients	 diagnosed	 in	 the	 neonatal	
period,	who	presented	with	 complete	hypopituitarism	at	diagnosis,	most	of	 the	patients	diagnosed	after	
investigation	for	growth	retardation	presented	a	progressive	impairment	of	the	residual	pituitary	function	
throughout	 childhood	 justifying	periodic	monitoring	 for	 additional	hormonal	deficiencies	 in	patients	with	
pituitary	stalk	 interruption	syndrome	[9].	Similar	 results	were	 found	 in	 two	other	studies	 in	children	with	
pituitary	 stalk	 interruption	 syndrome.	 In	 the	 first	 study	 of	 35	 children	 with	 GHD	 and	 pituitary	 stalk	
interruption	syndrome,	GHD	was	 isolated	in	40.6%	and	combined	with	other	pituitary	deficiencies	 in	10%	
of	patients	below	11	years	of	age	but	CPHD	was	consistent	at	completion	of	growth	in	all	patients	[10].	In	
the	 second	 study	on	83	 children	with	pituitary	 stalk	 interruption	 syndrome,	 all	 patients	had	GHD,	79.5%	
had	deficiency	 in	TSH,	67.5%	in	ACTH,	65.1%	in	LH/FSH,	and	14.5%	in	PRL.	 IGHD	was	found	 in	only	6%	of	
patients	[11].	Among	26	children	and	young	adults	with	pituitary	stalk	dysgenesis	(range	at	diagnosis:	2-27	
years),	 at	 first	 assessment,	 92.3%	 of	 patients	 had	GHD,	 26.9%	 had	 CPHD	 and	 7.6%	
panhypopituitarism.	Hormone	deficiencies	were	progressive	during	follow-up	in	84.6%;	96%	progressed	to	
multiple	pituitary	hormone	deficiencies	and	46%	to	panhypopituitarism	[12].	In	another	study,	the	gradual	
loss	 of	 anterior	 pituitary	 function	 was	 evaluated	 in	 28	 children	 with	 an	 invisible	 (n:18)	 or	 thin	 (n:10)	
pituitary	 stalk	on	MRI.	All	 the	patients	had	GHD	upon	 initial	evaluation.	At	 their	 last	visit	 (ages:	10	 to	24	
years),	 24	 patients	 had	 TSH	 deficiency,	 18	 ACTH	 deficiency,	 19	 gonadotropin	 deficiency,	 and	 3	Diabetes	
Insipidus	(DI).	An	ectopic	posterior	pituitary	lobe	was	present	in	23	patients	and	the	anterior	pituitary	was	
judged	 to	 be	 absent	 or	 small	 in	 20	of	 the	patients	 [13].	 In	 a	 recent	 large	 (n:8230)	international	pediatric	
database	 (GeNeSIS)	 additional	 hormonal	 deficiencies	 were	 found	 in	 37.5%	 of	 patients	 with	
structural	abnormalities,	47.5%	of	patients	with	known	genetic	defects	(TSH	>ACTH	>LH/FSH>ADH)	vs	3.8%	
in	 the	 idiopathic	 cases	 [7].	 In	a	2	 year	prospective	pediatric	 study,	 authors	analyzed	data	 from	13	young	
adults	with	childhood-onset	GHD	associated	with	ectopic	posterior	pituitary	and	“normal”	GH	response	at	
the	time	of	first	assessment	of	GH	secretion	(GH	peak	after	stimulation	test	between	5	and	10	µg/l).	Two	
years	after	the	retesting,	eight	of	13	patients	(61%)	developed	additional	anterior	pituitary	deficits.	Adrenal	
insufficiency	 was	 found	 in	 five	 patients,	 central	 hypothyroidism	 was	 diagnosed	 in	 four,	 and	
hypogonadotropic	hypogonadism	in	one	[14].		
Finally,	 in	 a	 large	 observational	 prospective	 study	 (KIMS	 study)	 on	 165	 adults	 with	 severe	 IGHD	 due	 to	
organic	 causes	 (malignancies	 or	 traumatic	 brain	 injury),	 new	 deficiencies	 were	 observed	 in	 35%	 of	 the	
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patients,	occurring	up	to	11	years	from	initial	assessment.	Secondary	hypothyroidism	was	the	most	often	
recorded	 new	 deficiency	 followed	 by	 secondary	 hypogonadism	 and	 secondary	 hypoadrenalism,	whereas	
ADH	deficiency	did	not	evolve	in	IGHD	[15].	
To	 summarize,	 the	 risk	 of	 progression	 from	 IGHD	 to	 CPHD	 in	 children	 varies	 depending	 on	 the	 etiology	
(5.5%	idiopathic	vs	20.7%	organic).	The	highest	risk	 is	displayed	by	children	with	abnormalities	 in	the	H-P	
region	 and	 ranges	 between	 35%	 when	 considering	 all	 the	 H-P	 abnormalities	 (including	 small	 anterior	
pituitary),	 85%	 in	 cases	 with	 pituitary	 stalk	 dysgenesis,	 and	 45-100%	 in	 children	 with	 pituitary	 stalk	
interruption	 syndrome.	 Interestingly,	 development	 of	 additional	 pituitary	 deficiencies	 was	 documented	
also	 in	61%	of	young	adults	with	childood	onset	GHD	due	to	ectopic	posterior	pituitary	and	a	normal	GH	
response	 to	 Insulin	 Tolerance	 Test	 (ITT)	 at	 time	 of	 retesting.	 Finally,	 the	 prevalence	 of	 progression	 from	
IGHD	to	CPHD	in	adult-onset	organic	severe	GHD,	has	been	reported	as	35%	(higher	than	in	children	with	
organic	GHD	(20.7%)	but	lower	than	in	children	with	H-P	abnormalities	(35-100%)).	
Heterogeneous	data	have	been	reported	on	the	type	and	timing	of	onset	of	additional	pituitary	hormone	
deficits.	This	heterogeneity	can	probably	be	explained	by	the	different	populations	included	in	the	studies	
in	terms	of	GHD	etiology	(organic	vs	idiopathic),	age	at	GHD	diagnosis	(pediatric	vs	adult)	and	duration	of	
follow-up	(short	vs	 long	term	follow-up).	TSH	deficiency	was	the	most	frequent	and	DI	the	 least	 frequent	
additional	deficit	 in	the	majority	of	the	studies,	whereas	the	prevalence	of	ACTH	and	LH/FSH	deficiencies	
was	variable.	Inconsistent	data	have	been	reported	in	the	two	studies	documenting	the	timing	of	evolution	
of	 endocrinopathies	 with	 TSH	 being	 the	 earliest	 and	 LH/FSH	 the	 latest	 deficit	 in	 one	 study	 and	 DI	 the	
earliest	 and	 ACTH	 the	 latest	 in	 another	 study.	 This	 heterogeneity	 could	 be	 partially	 explained	 by	 the	
different	age	and	length	of	follow-up	of	the	populations	studied,	but	could	also	genuinely	reflect	the	highly	
variable	endocrine	phenotype	displayed	by	patients	with	CPHD.		
	
Childhood-onset	IGHD	and	risk	of	central	hypoadrenalism	in	adulthood	
		
Few	 studies	 focused	 on	 the	 risk,	 in	 patients	 with	 childhood-onset	 GHD,	 of	 developing	 central	
hypoadrenalism	later	in	life	and	therefore	on	the	need,	in	these	patients,	for	lifelong	monitoring	for	ACTH	
deficiency.	
In	a	cross-sectional	study	assessing	the	relationship	between	GH,	TSH	and	ACTH	deficiency	in	236	patients		
with	 childhood-onset	 idiopathic	 GHD,	 nine	 were	 found	 to	 have	 ACTH	 deficiency	 (4%)	 and	 21	 (9%)	 TSH	
deficiency.	 All	 of	 the	 ACTH-deficient	 subjects	 were	 also	 TSH	 deficient.	 Eight	 of	 the	 nine	 ACTH-deficient	
subjects	had	a	midline	abnormality	on	MRI	 (ectopic	posterior	pituitary	or	 interrupted	 stalk).	 The	authors	
concluded	that	ACTH	deficiency	was	highly	unlikely	 in	the	setting	of	normal	pituitary	anatomy	[16].	Some	
sporadic	 cases	 have	 been	 reported	 of	 patients	 with	 IGHD	 developing	 ACTH	 deficiency	 during	 adult	 life.	
However,	 in	 keeping	 with	 the	 results	 from	 the	 previous	 study,	 all	 of	 these	 patients	 had	 either	 TSH	
deficiency	 or	 a	 gross	 anatomical	 abnormality	 of	 the	 H-P	 region	 [17,	 18].	 Conversely,	 in	 another	 cross-
sectional	study,	the	authors	documented	a	significant	risk	of	adult	adrenal	insufficiency	in	childhood	onset	
idiopathic	GHD.	In	this	study,	24	children	treated	for	idiopathic	IGHD	and	in	whom	GH	treatment	had	been	
discontinued	at	 the	end	of	 linear	growth	were	called	back	for	a	reassessment	of	GH	and	ACTH	secretion.	
Eleven	of	24	patients	(45%)	showed	a	subnormal	cortisol	response	to	Synacthen	test.	Five	of	these	patients	
had	 impaired	 adrenal	 function	 in	 the	 absence	 of	 adult	 GHD.	 Cortisol	 concentrations	 were	 lower	 in	
adulthood,	 compared	 with	 results	 obtained	 in	 adolescence	 [19].	 Similarly,	 Di	 Iorgi	 et	 al	 reported	
development	of	ACTH	Deficiency	in	38.5%	of	13	young	adults	treated	in	childhood	for	GHD	due	to	ectopic	
posterior	pituitary	and	who	had	a	normal	GH	response	to	ITT	(5-10	µg/L)	at	retesting	[14]	and	Miyamoto	et	
al	documented	a	gradual	evolution	of	ACTH	deficiency	over	time	with	suboptimal	cortisol	peaks	in	response	
to	 ITT	 in	24%	(before	age	10	years)	and	56%	(before	age	25	years)	of	patients	with	prenatal	or	perinatal-
onset	 hypopituitarism	 and	 an	 invisible	 or	 thin	 pituitary	 stalk	 [13].	 These	 findings	 show	 that	 there	 is	 a	
potentially	 increased	risk	of	undiagnosed	adrenal	 insufficiency	 in	patients	with	idiopathic	childhood	onset	
IGHD	 (even	 in	 absence	 of	 H-P	 abnormalities,	 TSH	 Deficiency	 and	 adult	 GHD),	 stressing	 the	 need	 for	
continuous,	 regular	 endocrine	 evaluation	 in	 order	 to	 prevent	 a	 missed	 diagnosis	 of	 a	 silently	 evolving,	
potentially	lethal,	adrenal	insufficiency	[19].		
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GH	treatment	and	development	of	central	hypothyroidism		
	
There	 is	 some	 evidence	 suggesting	 that	 GH	 deficiency	 masks	 central	 hypothyroidism	 in	 a	 significant	
proportion	of	hypopituitary	patients,	and	this	may	be	unmasked	after	commencement	of	GH	replacement.	
The	 mechanism	 of	 development	 of	 central	 hypothyroidism	 post-GH	 remains	 unclear.	 	 The	 start	 of	 GH	
therapy	has	 been	 associated	with	 a	 decrease	 in	 FT4	 concentrations	 in	 the	 absence	of	 significant	 parallel	
changes	 in	 FT3	 and	 TSH	 concentrations.	 Two	 mechanisms	 have	 been	 suggested	 to	 explain	 the	 above	
discrepancies.	The	first	points	to	an	inhibition	of	TSH	release	mediated	by	an	increased	somatostatinergic	
tone	directly	 induced	by	GH.	 Indeed,	 Jorgensen	 et	 al	 documented	a	 significant	 blunting	of	 the	nocturnal	
TSH	 surge	 after	 the	 administration	 of	 GH	 to	 GHD	 adults	 [20].	 The	 second	 proposes	 an	 increased	
extrathyroidal	conversion	of	T4	to	T3	or	an	enhancement	of	T4	to	T3	deiodination	possibly	mediated	by	the	
generation	of	IGF-1	[20].		
In	 a	 study	of	20	euthyroid	 children	with	 idiopathic	 IGHD	and	6	 children	with	CPHD	 secondary	 to	organic	
lesions,	GH	replacement	therapy	induced	central	hypothyroidism	only	in	children	with	CPHD	[21].	Stronger	
evidence	 was	 found	 in	 a	 large	 cohort	 study	 of	 243	 severely	 GH-deficient	 adults,	 whereby	 36%	 of	 the	
previously	 euthyroid	 GHD	 patients	 developed	 central	 hypothyroidism	 after	 the	 start	 of	 GH	 treatment.	
Additionally	16%	of	the	patients	who	were	already	hypothyroid	before	the	start	of	GH	treatment	needed	an	
increase	in	the	L-T4	dose.	Patients	at	higher	risk	of	developing	post-GH	hypothyroidism	included	those	with	
a	serum	T4	concentration	towards	the	lower	end	of	the	normal	reference	range	[22].	The	results	of	these	
studies	 seem	 to	 suggest	 that	 GH	 treatment	 unmasks	 central	 hypothyroidism	 mainly	 in	 patients	 with	
“organic”	GHD.	However,	a	recent	review	concluded	with	the	recommendation	that	all	patients	starting	GH	
should	have	their	thyroid	function	monitored	closely,	particularly	in	the	first	6	months	following	the	onset	
of	treatment,	to	identify	those	who	will	develop	hypothyroidism	[23].	
	
Risk	factors	for	progression	from	IGHD	to	CPHD	
	
The	risk	factors	for	progression	from	IGHD	to	CPHD	are	listed	in	Table	2.	
	
Etiology	of	IGHD	(organic	vs	idiopathic)	
The	 risk	of	developing	CPHD	 in	 children	with	organic	 vs	 idiopathic	 IGHD	has	been	assessed	 in	a	 large	 (n:	
5805)	 prospective	 paediatric	 study.	 Children	 who	 developed	 CPHD	 had	 more	 frequently	 a	 diagnosis	 of	
intracranial	tumour	or	mutations	in	genes	controlling	H-P	development	and/or	function	as	compared	with	
those	 with	 idiopathic	 GHD	 [4].	 Conversely,	 in	 a	 study	 of	 165	 IGHD	 and	 3006	 CPHD	 adult	 patients,	
progression	 from	 IGHD	 into	 CPHD	 was	 not	 predicted	 by	 the	 etiology	 nor	 by	 a	 history	 of	 surgery	 or	
radiotherapy	[15].	Taken	together,	the	results	of	these	two	studies	suggest	that	organic	GHD	is	more	likely	
to	progress	to	CPHD	than	idiopathic	GHD;	however	within	the	organic	cases,	the	specific	etiology	(surgery	
vs	radiotherapy	vs	malignancies)	does	not	predict	the	risk	of	progression	to	CPHD.	
	
Structural	abnormalities	of	the	forebrain	and	H-P	region	
Several	 groups	 have	 studied	 the	 correlation	 between	 H-P	 congenital	 abnormalities	 and	 development	 of	
anterior	pituitary	hormone	deficiencies.	An	association	between	specific	H-P	abnormalities	and	progression	
to	CPHD	has	been	documented	in	most,	but	not	all,	studies.	
In	 a	 recent	 study	 of	 121	 children	 with	 IGHD	 (n=81)	 and	 CPHD	 (n=40),	 IGHD	 patients	 showing	 absent	
pituitary	 stalk	 and	ectopic	 posterior	 pituitary	 (n=5)	 inevitably	developed	additional	 hormone	deficiencies	
[24].	Similarly,	 in	83	patients	with	childhood	onset	 IGHD,	pituitary	stalk	abnormalities	were	the	strongest	
risk	factor	(3.28	fold)	for	the	development	of	CPHD	[6].	Partially	in	contrast	with	previous	results,	in	a	study	
of	 31	 children	with	 congenital	 hypopituitarism,	 empty	 sella	 and	 stalk	 abnormalities	were	 reported	more	
frequently	 in	 CPHD	 than	 in	 the	 IGHD	 group,	 but	 a	 hypoplastic	 pituitary	 gland,	 posterior	 pituitary	
abnormalities	 and	 the	MRI	 tetrad	 (empty	 sella,	 absent/hypoplastic	 anterior	 pituitary,	 absent/redundant	
stalk,	posterior	pituitary	abnormalities)	were	more	prevalent	in	IGHD	than	in	CPHD	and	correlated	with	the	
severity	of	GH	deficiency.	In	this	paper	imaging	abnormalities	correlated	best	with	severity	of	GH	deficiency	
rather	than	number	of	hormone	deficiencies	[25].	
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Several	 other	 authors	 have	 focused	 on	 the	 association	 between	 stalk	 abnormalities	 and	 the	 risk	 of	
developing	 CPHD.	 The	 first	 study	 documenting	 a	 strong	 association	 between	 absent	 pituitary	 stalk	 after	
gadolinium	 injection	 and	 CPHD	was	 performed	 on	 18	 children	 (8	with	 IGHD	 and	 10	with	 CPHD)	with	 an	
unidentified	pituitary	 stalk	 at	 first	 MRI,	 who	 were	 then	 re-evaluated	 with	 MRI	 using	 gadopentetate	
dimeglumine	(Gd-DTPA).	After	Gd-DTPA,	patients	with	absent	pituitary	stalk	had	a	risk	of	developing	CPHD	
27	times	greater	than	had	those	with	an	identified	pituitary	stalk.	The	vascular	component	of	the	pituitary	
stalk	was	easily	recognized	after	Gd-DTPA	in	most	 IGHD	patients,	but	exceptionally	 in	CPHD,	whereas	the	
neural	 component	was	 lacking	 regardless	 of	whether	 patients	 had	 IGHD	or	CPHD	 [26].	 In	 a	 recent	 study	
comparing	 39	 patients	with	 CPHD	with	 46	 patients	with	 IGHD,	 all	 patients	whose	 infundibulum	was	 not	
visualized	after	Gd-DTPA	injection	belonged	to	the	CPHD	group	[27].	Similar	results	were	found	in	another	
study	of	25	children	with	GHD	and	ectopic	posterior	pituitary	divided	in	two	groups	based	on	the	visibility	
(Group	1)	or	absence	(Group	2)	of	the		after	gadolinium	injection.	Most	patients	in	group	1	(12	of	14	cases)	
showed	 IGHD;	 on	 the	 other	 hand,	 all	 but	 one	 patient	 in	 group	 2	 showed	CPHD.	 Additionally,	 an	 ectopic	
posterior	pituitary	at	the	level	of	the	median	eminence	was	found	in	all	group	2	patients	and	in	6	of	the	14	
group	1	patients,	whereas	the	ectopic	posterior	pituitary	was	located	at	various	points	along	the	pituitary	
stalk	in	the	other	8	patients	within	group	1.	The	height	of	the	adenohypophysis	was	smaller	in	group	2,	and	
when	 correlated	 with	 age	 and	 pubertal	 status,	 the	 prevalence	 of	 anterior	 pituitary	 hypoplasia	 was	 also	
higher	 in	 group	 2.	 Although	 the	 pathogenesis	 of	 GH	 deficiency	 with	 ectopic	 posterior	 pituitary	 remains	
unclear,	these	results	suggest	that	in	cases	of	GHD	associated	with	ectopic	posterior	pituitary,	patients	with	
no	visible	pituitary	stalk	on	MRI	after	gadolinium	injection	present	a	more	severe	form	of	the	disease	with	
CPHD,	whereas	visibility	of	 the	pituitary	stalk	 is	associated	with	 IGHD.	The	results	of	 the	study	also	show	
that	posterior	pituitary	location	along	the	stalk	is	a	significant	protective	factor	for	the	severity	of	hormonal	
phenotype,	with	a	greater	number	of	hormone	deficiencies	present	when	the	posterior	lobe	is	localized	at	
the	median	eminence	or	 in	 the	hypothalamic	 region	 [28].	 In	 contrast	 to	 these	previous	 studies,	 a	 recent	
study	of	26	patients	with	partial	or	complete	absence	of	pituitary	 stalk	associated	with	anterior	pituitary	
hypoplasia	 or	 ectopic	 posterior	 pituitary	 failed	 to	 document	 a	 significant	 association	 between	 hormonal	
dysfunction	and	pituitary	stalk	visibility	or	the	location	of	the	ectopic	posterior	pituitary	[12].		
It	is	well	known	that	midline	brain	abnormalities	and	optic	nerve	hypoplasia,	in	addition	to	defects	in	the	H-
P	 region,	 are	 also	 associated	with	 a	 higher	 risk	 of	 developing	 hypopituitarism.	 Patients	with	 septo-optic	
dysplasia	have	been	found	to	present	with	some	degree	of	hypopituitarism	in	50-66%	of	cases	[29-34].	In	a	
retrospective	 study	of	MRI	 findings	 and	endocrine	 function	on	170	 children	with	or	 ‘at-risk’	 (optic	 nerve	
hypoplasia,	holoprosencephaly	or	multiple	midline	systemic	defects)	of	congenital	hypopituitarism,	the	risk	
of	 hypopituitarism	 was	 27	 times	 greater	 in	 patients	 with	 ectopic	 posterior	 pituitary.	 Anterior	 pituitary	
hypoplasia	and	pituitary	stalk	absence	were	also	significantly	associated	with	hypopituitarism.	With	respect	
to	 the	 type	 or	 severity	 of	 hypopituitarism,	 CPHD	 was	 more	 often	 associated	 with	 an	 abnormal	 corpus	
callosum	 and	 stalk	 abnormalities.	 Overall,	 midline	 forebrain	 defects	 were	 5.2	 times	 more	 prevalent	 in	
patients	with	CPHD	as	 compared	with	 IGHD	 [34].	 The	 result	 of	 this	 study	 confirm	 that	midline	 forebrain	
defects	are	associated	with	a	higher	risk	of	CPHD,	but	also	suggest	that	within	children	at	risk	of	developing	
hypopituitarism	due	to	the	presence	of	optic	nerve	hypoplasia	and/or	midline	brain	abnormalities,	corpus	
callosum	and	pituitary	stalk	abnormalities	are	strong	predictors	of	CPHD.		
To	 summarize,	 HP,	ON	 and	midline	 brain	 abnormalities	 have	 been	 reported	more	 frequently	 in	 children	
with	CPHD	compared	 to	 IGHD.	absent	pituitary	 stalk,	particularly	 in	 its	 vascular	 component,	 seems	 to	be	
the	 strongest	 predictor	 of	 the	 development	 of	 additional	 pituitary	 deficits	 in	 IGHD.	 An	 ectopic	 posterior	
pituitary,	 especially	when	 located	 at	 the	median	 eminence	 or	 the	 hypothalamic	 level,	 has	 been	 strongly	
associated	with	development	of	additional	pituitary	deficits.	Corpus	callosum	abnormalities	are	associated	
with	CPHD,	whereas	anterior	pituitary	hypoplasia	can	be	found	both	in	IGHD	and	CPHD.	However,	an	empty	
sella	 is	more	 likely	to	be	associated	with	CPHD	and	the	degree	of	hypoplasia	of	the	adenohypophysis	has	
been	associated	with	the	number	and	severity	of	pituitary	deficits.	Regarding	the	type	of	pituitary	deficits,	
H-P	 abnormalities	 (ectopic	 posterior	 pituitary	 and	 absent	 pituitary	 stalk)	 are	 more	 frequently	 found	 in	
association	with	ACTH	and	TSH	than	FSH/LH	deficiency.	
	
Genetic	defects	
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IGHD	can	present	as	a	result	of	defects	in	genes	involved	in	pituitary	development	or	in	the	GH	secretory	
pathway.	The	past	decades	have	witnessed	an	explosion	 in	our	understanding	of	the	development	of	the	
anterior	 pituitary	 gland	 and	 of	mechanisms	 that	 underlie	 the	 diagnosis	 of	 GHD	 and	 CPHD.	 However,	 to	
date,	genetic	mutations	have	been	identified	only	in	a	modest	proportion	of	patients.	It	is	clear	that	many	
genes	remain	to	be	 identified	and	the	characterization	of	these	will	 further	elucidate	the	pathogenesis	of	
these	complex	conditions	[35].	
Transcription	 factors	 such	 as	 HESX1,	 PROP1,	 POU1F1,	 LHX3,	 LHX4,	 SOX2	 and	 SOX3	 are	 involved	 in	 the	
etiology	of	CPHD	and	 they	are	associated	with	highly	variable	phenotypes	encompassing	 IGHD,	CPHD,	or	
more	 complex	 disorders	 such	 as	 septo-optic	 dysplasia	 [35-38].	 PROP1	 mutations	 constitute	 the	 most	
common	 genetic	 cause	 for	 CPHD	 ([9,	 39,	 40]	 [41])	 with	 a	 poor	 genotype-phenotype	 correlation	 and	
different	pattern	of	evolution	of	endocrinopathies	([42],[12]).		
Mutation	 in	 GH1	 had	 been	 historically	 associated	 with	 isolated	 congenital	 GHD.	 However	 evolution	 of	
additional	deficits	including	ACTH,	TSH,	PRL,	LH/FSH	has	been	subsequently	documented	[38].	In	a	study	of	
57	subjects	belonging	to	19	 families	harbouring	different	splice	site	as	well	as	missense	mutations	within	
GH-1,	subjects	presenting	with	a	splice	site	mutation	within	the	first	2	bp	of	intervening	sequence	3	(5’IVS	+	
1/+2	bp)	leading	to	a	skipping	of	exon	3	were	found	to	be	more	likely	to	develop	other	pituitary	hormone	
deficiencies,	 mainly	 ACTH	 and	 TSH.	 In	 addition,	 although	 the	 patients	 with	 missense	 mutations	 had	
previously	been	reported	to	be	less	affected,	a	number	of	patients	presenting	with	the	P89L	missense	GH1	
form	 showed	 some	 additional	 pituitary	 hormone	 impairment.	 	 The	 development	 of	 multiple	 hormonal	
deficiencies	was	not	age-dependent,	and	there	was	a	great	variability	 in	onset,	severity,	and	progression,	
even	 within	 families	 with	 the	 same	 mutation	 [43].	 A	 recent	 paper	 has	 also	 described	 evolution	 of	
gonadotropin	 deficiency	 in	 one	 adult	 treated	 for	 childhood	 onset	 IGHD	 due	 to	 an	 autosomal	 dominant	
splicing	mutation	in	GH-1	(intervening	sequence-3	+	1G>A)	[44].		The	message	of	clinical	importance	from	
the	previous	studies	is	that	the	pituitary	endocrine	status	of	patients	with	GH1	mutations	should	continue	
to	be	monitored	closely	over	the	years	because	further	hormonal	deficiencies	may	evolve	with	time.	
Taken	 together,	 the	 results	 of	 the	 above	 reported	 studies	 show	 that,	 in	 congenital	 forms	 of	 IGHD,	 the	
presence	of	certain	genetic	defects	in	transcription	factors	involved	in	H-P	development	or	in	GH	secretion	
can	predispose	to	a	higher	risk	of	developing	additional	pituitary	deficits.	However	the	genotype-phenotype	
correlation	is	poor	and	the	endocrine	phenotype	is	highly	variable	in	these	patients.		
	
	
Duration	of	follow-up		
In	a	large	prospective	study	of	5805	pediatric	patients	with	idiopathic	IGHD,	the	duration	of	follow-up	was	
the	 strongest	 predictor	 of	 evolving	 endocrinopathies	 [4].	A	 similar	 correlation	was	 found	 in	 716	 children	
with	 organic	 IGHD	 from	 the	 same	 database	 [5].	 Hence,	 long-term	 monitoring	 of	pituitary	function	 is	
recommended,	irrespective	of	the	etiology	of	GHD.	
	
Severity	of	GHD	
In	 the	 study	by	Blum	et	 al.,	 predictors	 of	 evolution	of	 endocrinopathy	 in	 IGHD	patients	 included	 a	more	
severe	GHD	phenotype,	as	 reflected	by	 lower	baseline	height	SDS	and	peak	stimulated	GH;	children	who	
developed	CPHD	also	had	a	better	first-year	response	to	GH	therapy,	in	keeping	with	the	more	severe	GHD.	
However,	 importantly,	 the	 presence	 of	 milder	 forms	 of	 GHD	 did	 not	 appear	 to	 exclude	 the	 future	
development	 of	 CPHD:	 ten	 patients	 who	 developed	 CPHD	 were	 initially	 diagnosed	 as	 having	 GH	
neurosecretory	 dysfunction	 and	 20	 patients	 had	 peak	 GH	 concentrations	 above	 the	 generally	 used	
diagnostic	 cut-off	 for	 GHD	 of	 10	 μg/l	 [4].	 A	 correlation	 between	 the	 severity	 of	 GHD	 and	 the	 risk	 of	
developing	 additional	 pituitary	 deficiencies	 has	 also	 been	 documented	 in	 children	with	 organic	GHD	 [5].	
The	results	of	these	studies	suggest	that	children	with	severe	IGHD	display	a	higher	risk	of	developing	CPHD	
irrespective	of	the	underlying	etiology.	However,	the	presence	of	milder	forms	of	GHD	does	not	exclude	the	
future	development	of	CPHD.		
	
Gender:	
In	two	studies	female	gender	was	a	predictor	of	CPHD	development	in	children	with	IGHD	[5,	Otto	Pituitary	
2015,	6].		
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Perinatal/neonatal	history	
In	a	 large	prospective	study	of	children	with	idiopathic	IGHD,	delivery	complications,	breech	delivery,	and	
perinatal/neonatal	adverse	events	had	occurred	more	 frequently	 in	patients	who	developed	CPHD	[4].	 In	
another	study	of	31	children	with	congenital	hypopituitarism,	78%	of	children	in	the	breech	delivery	group,	
70%	in	the	vertex	group	and	50%	in	the	lower	segment	caesarian	section	group	had	CPHD	[25].	Conversely,	
in	 a	 retrospective	 and	 prospective	 study	 of	 26	 patients	 with	 pituitary	 stalk	 dysgenesis,	 no	 significant	
association	was	 found	between	hormonal	dysfunction	and	previous	perinatal	 damage	or	breech	delivery	
[12].	 To	 conclude,	 an	 association	 between	 the	 evolution	 of	 endocrinopathy	 and	 delivery	 complications,	
breech	delivery,	and	perinatal/neonatal	adverse	events	has	been	found	in	some,	but	not	all,	studies.	
	
Extra-pituitary	malformations		
In	 a	 study	 of	 a	 cohort	 of	 pituitary	 stalk	 interruption	 syndrome	 patients	 comparing	 subgroups	 with	 or	
without	 extra-pituitary	 malformations,	 CPHD	 was	 observed	 significantly	 more	 often	 in	 patients	 with,	
compared	with	 those	without,	 extra-pituitary	malformations	 (87.5	 vs	 69.5%	 respectively).	 Extra-pituitary	
malformations	included	CNS,	ocular,	dental,	craniofacial,	sella	turcica,	or	cardiac	malformations	[11].			
	
Conclusions:	
	
Children	with	IGHD	display	a	significant	risk	of	developing	additional	pituitary	deficiencies.	This	risk	ranges	
between	5.5%	in	childhood-onset	idiopathic	IGHD	and	35%	in	adult-onset	organic	IGHD.	H-P,	optic	nerves	
and	midline	brain	abnormalities	predispose	to	a	higher	risk	of	developing	additional	pituitary	deficits	(up	to	
45-100%	 in	 children	 with	 pituitary	 stalk	 interruption	 syndrome).	 Absent	 pituitary	 stalk	 after	 gadolinium	
administration	and	an	ectopic	posterior	pituitary	at	the	median	eminence	and	hypothalamic	level	are	highly	
predictive	of	CPHD.	Empty	 sella,	 absent/hypoplastic	 corpus	 callosum	and	optic	nerve	hypoplasia	are	also	
associated	with	a	higher	risk	of	evolution	of	endocrinopathy.	The	type	and	age	at	occurrence	of	additional	
pituitary	deficits	are	highly	variable	and	they	cannot	be	easily	predicted	based	on	the	etiology,	severity	and	
age	at	onset	of	IGHD.	Importantly,	 idiopathic	IGHD	without	structural	H-P	abnormalities	does	not	exclude	
the	occurrence	of	additional	pituitary	deficits.	A	longer	duration	of	follow-up	is	associated	with	a	higher	risk	
of	 additional	 pituitary	 deficits,	 suggesting	 that	 hypopituitarism	 is	 a	 dynamic	 condition	 where	 new	
deficiencies	can	appear	years	after	the	initial	diagnosis.	Adrenal	insufficiency	can	silently	evolve	years	after	
the	onset	of	GHD	and	the	start	of	GH	treatment	in	patients	with	GHD	can	unmask	central	hypothyroidism.				
To	 conclude,	 the	 current	 available	 evidence	 supports	 longstanding	 recommendations	 for	 the	need,	 in	 all	
patients	 diagnosed	 with	 IGHD,	 of	 a	 careful	 and	 indefinite	 follow-up	 for	 additional	 pituitary	 hormone	
deficiencies,	 irrespective	 of	 the	 age	 at	 presentation,	 severity,	 etiology	 and	 of	 the	 reversibility	 of	 GHD	 in	
adolescence	[2].	
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